Risk for Myocarditis Low After BNT162b2 Booster in Israel

TUESDAY, Sept. 6, 2022 -- The risk estimate for myocarditis in the 30 days after receipt of a COVID-19 booster dose (BNT162b2) is 1.42 per 100,000 overall, with higher risk seen in young males, according to a research letter published online Sept. 5...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news